FibroGen Inc Total Liabilities
FibroGen Inc total liabilities. Based on the latest financial reports, FibroGen Inc (FGEN) has total liabilities worth $119.53 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check FibroGen Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of FibroGen Inc (2012–2024)
Total liabilities of FibroGen Inc from 2012 to 2024. This chart illustrates how FibroGen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of FibroGen Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
FibroGen Inc Competitors by Total Liabilities
The table below lists competitors of FibroGen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
USA | $43.37 Million |
|
Heidelberger Beteiligungsholding AG
F:IPOK
|
Germany | €276.00K |
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
USA | $1.31 Million |
|
Entain PLC
LSE:ENT
|
UK | GBX8.07 Billion |
|
Shian Yih Electronic Industry Co Ltd
TWO:3531
|
Taiwan | NT$386.12 Million |
|
REDCO PRP GROUP LTD -05
F:8KI
|
Germany | €45.24 Billion |
|
Kirklands Inc
NASDAQ:KIRK
|
USA | $241.63 Million |
|
Rising Dragon Acquisition Corp. Ordinary Shares
NASDAQ:RDAC
|
USA | $1.96 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down FibroGen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FibroGen Inc total assets.
Liquidity & Leverage Metrics
FibroGen Inc Total Liabilities Ratios Explained
FibroGen Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FibroGen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FibroGen Inc (2012–2024)
The table below shows the annual total liabilities of FibroGen Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $398.16 Million | -32.02% |
| 2023-12-31 | $585.73 Million | -4.23% |
| 2022-12-31 | $611.57 Million | +12.27% |
| 2021-12-31 | $544.71 Million | +41.34% |
| 2020-12-31 | $385.39 Million | +19.69% |
| 2019-12-31 | $321.99 Million | -8.56% |
| 2018-12-31 | $352.13 Million | +11.36% |
| 2017-12-31 | $316.20 Million | +7.39% |
| 2016-12-31 | $294.44 Million | +7.56% |
| 2015-12-31 | $273.75 Million | +12.72% |
| 2014-12-31 | $242.85 Million | +28.26% |
| 2013-12-31 | $189.35 Million | +32.04% |
| 2012-12-31 | $143.40 Million | -- |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more